Global Immunotherapy for Neuroblastoma Supply, Demand and Key Producers, 2023-2029
The global Immunotherapy for Neuroblastoma market size is expected to reach $ 63 million by 2029, rising at a market growth of 4.4% CAGR during the forecast period (2023-2029).
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report studies the global Immunotherapy for Neuroblastoma demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immunotherapy for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immunotherapy for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immunotherapy for Neuroblastoma total market, 2018-2029, (USD Million)
Global Immunotherapy for Neuroblastoma total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Immunotherapy for Neuroblastoma total market, key domestic companies and share, (USD Million)
Global Immunotherapy for Neuroblastoma revenue by player and market share 2018-2023, (USD Million)
Global Immunotherapy for Neuroblastoma total market by Type, CAGR, 2018-2029, (USD Million)
Global Immunotherapy for Neuroblastoma total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Immunotherapy for Neuroblastoma market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immunotherapy for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Immunotherapy for Neuroblastoma Market, By Region:
1. How big is the global Immunotherapy for Neuroblastoma market?
2. What is the demand of the global Immunotherapy for Neuroblastoma market?
3. What is the year over year growth of the global Immunotherapy for Neuroblastoma market?
4. What is the total value of the global Immunotherapy for Neuroblastoma market?
5. Who are the major players in the global Immunotherapy for Neuroblastoma market?
6. What are the growth factors driving the market demand?
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report studies the global Immunotherapy for Neuroblastoma demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Immunotherapy for Neuroblastoma, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Immunotherapy for Neuroblastoma that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Immunotherapy for Neuroblastoma total market, 2018-2029, (USD Million)
Global Immunotherapy for Neuroblastoma total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Immunotherapy for Neuroblastoma total market, key domestic companies and share, (USD Million)
Global Immunotherapy for Neuroblastoma revenue by player and market share 2018-2023, (USD Million)
Global Immunotherapy for Neuroblastoma total market by Type, CAGR, 2018-2029, (USD Million)
Global Immunotherapy for Neuroblastoma total market by Application, CAGR, 2018-2029, (USD Million)
This reports profiles major players in the global Immunotherapy for Neuroblastoma market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Immunotherapy for Neuroblastoma market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Immunotherapy for Neuroblastoma Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
1. How big is the global Immunotherapy for Neuroblastoma market?
2. What is the demand of the global Immunotherapy for Neuroblastoma market?
3. What is the year over year growth of the global Immunotherapy for Neuroblastoma market?
4. What is the total value of the global Immunotherapy for Neuroblastoma market?
5. Who are the major players in the global Immunotherapy for Neuroblastoma market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Immunotherapy for Neuroblastoma Introduction
1.2 World Immunotherapy for Neuroblastoma Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Immunotherapy for Neuroblastoma Total Market by Region (by Headquarter Location)
1.3.1 World Immunotherapy for Neuroblastoma Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.3 China Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.4 Europe Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.5 Japan Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.6 South Korea Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.7 ASEAN Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.8 India Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immunotherapy for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Immunotherapy for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.2 World Immunotherapy for Neuroblastoma Consumption Value by Region
2.2.1 World Immunotherapy for Neuroblastoma Consumption Value by Region (2018-2023)
2.2.2 World Immunotherapy for Neuroblastoma Consumption Value Forecast by Region (2024-2029)
2.3 United States Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.4 China Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.5 Europe Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.6 Japan Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.7 South Korea Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.8 ASEAN Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.9 India Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
3 WORLD IMMUNOTHERAPY FOR NEUROBLASTOMA COMPANIES COMPETITIVE ANALYSIS
3.1 World Immunotherapy for Neuroblastoma Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Immunotherapy for Neuroblastoma Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Immunotherapy for Neuroblastoma in 2022
3.2.3 Global Concentration Ratios (CR8) for Immunotherapy for Neuroblastoma in 2022
3.3 Immunotherapy for Neuroblastoma Company Evaluation Quadrant
3.4 Immunotherapy for Neuroblastoma Market: Overall Company Footprint Analysis
3.4.1 Immunotherapy for Neuroblastoma Market: Region Footprint
3.4.2 Immunotherapy for Neuroblastoma Market: Company Product Type Footprint
3.4.3 Immunotherapy for Neuroblastoma Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Immunotherapy for Neuroblastoma Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Immunotherapy for Neuroblastoma Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Immunotherapy for Neuroblastoma Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Immunotherapy for Neuroblastoma Consumption Value Comparison
4.2.1 United States VS China: Immunotherapy for Neuroblastoma Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Immunotherapy for Neuroblastoma Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Immunotherapy for Neuroblastoma Companies and Market Share, 2018-2023
4.3.1 United States Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
4.4 China Based Companies Immunotherapy for Neuroblastoma Revenue and Market Share, 2018-2023
4.4.1 China Based Immunotherapy for Neuroblastoma Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
4.5 Rest of World Based Immunotherapy for Neuroblastoma Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Immunotherapy for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Dinutuximab
5.2.2 Naxitamab
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
5.3.2 World Immunotherapy for Neuroblastoma Market Size by Type (2024-2029)
5.3.3 World Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Immunotherapy for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
6.3.2 World Immunotherapy for Neuroblastoma Market Size by Application (2024-2029)
6.3.3 World Immunotherapy for Neuroblastoma Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 United Therapeutics
7.1.1 United Therapeutics Details
7.1.2 United Therapeutics Major Business
7.1.3 United Therapeutics Immunotherapy for Neuroblastoma Product and Services
7.1.4 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 United Therapeutics Recent Developments/Updates
7.1.6 United Therapeutics Competitive Strengths & Weaknesses
7.2 Y-mAbs Therapeutics
7.2.1 Y-mAbs Therapeutics Details
7.2.2 Y-mAbs Therapeutics Major Business
7.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product and Services
7.2.4 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Y-mAbs Therapeutics Recent Developments/Updates
7.2.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.3 EUSA Pharma
7.3.1 EUSA Pharma Details
7.3.2 EUSA Pharma Major Business
7.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Product and Services
7.3.4 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 EUSA Pharma Recent Developments/Updates
7.3.6 EUSA Pharma Competitive Strengths & Weaknesses
7.4 ANI Pharmaceuticals
7.4.1 ANI Pharmaceuticals Details
7.4.2 ANI Pharmaceuticals Major Business
7.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.4.4 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 ANI Pharmaceuticals Recent Developments/Updates
7.4.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Baxter Healthcare
7.5.1 Baxter Healthcare Details
7.5.2 Baxter Healthcare Major Business
7.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Product and Services
7.5.4 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Baxter Healthcare Recent Developments/Updates
7.5.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.6 Ingenus Pharmaceuticals
7.6.1 Ingenus Pharmaceuticals Details
7.6.2 Ingenus Pharmaceuticals Major Business
7.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.6.4 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.6.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Pfizer
7.7.1 Pfizer Details
7.7.2 Pfizer Major Business
7.7.3 Pfizer Immunotherapy for Neuroblastoma Product and Services
7.7.4 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Pfizer Recent Developments/Updates
7.7.6 Pfizer Competitive Strengths & Weaknesses
7.8 Hikma Pharmaceuticals
7.8.1 Hikma Pharmaceuticals Details
7.8.2 Hikma Pharmaceuticals Major Business
7.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.8.4 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Hikma Pharmaceuticals Recent Developments/Updates
7.8.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Details
7.9.2 Teva Pharmaceuticals Major Business
7.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.9.4 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Teva Pharmaceuticals Recent Developments/Updates
7.9.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Immunotherapy for Neuroblastoma Industry Chain
8.2 Immunotherapy for Neuroblastoma Upstream Analysis
8.3 Immunotherapy for Neuroblastoma Midstream Analysis
8.4 Immunotherapy for Neuroblastoma Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Immunotherapy for Neuroblastoma Introduction
1.2 World Immunotherapy for Neuroblastoma Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Immunotherapy for Neuroblastoma Total Market by Region (by Headquarter Location)
1.3.1 World Immunotherapy for Neuroblastoma Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.3 China Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.4 Europe Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.5 Japan Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.6 South Korea Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.7 ASEAN Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.3.8 India Immunotherapy for Neuroblastoma Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Immunotherapy for Neuroblastoma Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Immunotherapy for Neuroblastoma Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.2 World Immunotherapy for Neuroblastoma Consumption Value by Region
2.2.1 World Immunotherapy for Neuroblastoma Consumption Value by Region (2018-2023)
2.2.2 World Immunotherapy for Neuroblastoma Consumption Value Forecast by Region (2024-2029)
2.3 United States Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.4 China Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.5 Europe Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.6 Japan Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.7 South Korea Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.8 ASEAN Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
2.9 India Immunotherapy for Neuroblastoma Consumption Value (2018-2029)
3 WORLD IMMUNOTHERAPY FOR NEUROBLASTOMA COMPANIES COMPETITIVE ANALYSIS
3.1 World Immunotherapy for Neuroblastoma Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Immunotherapy for Neuroblastoma Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Immunotherapy for Neuroblastoma in 2022
3.2.3 Global Concentration Ratios (CR8) for Immunotherapy for Neuroblastoma in 2022
3.3 Immunotherapy for Neuroblastoma Company Evaluation Quadrant
3.4 Immunotherapy for Neuroblastoma Market: Overall Company Footprint Analysis
3.4.1 Immunotherapy for Neuroblastoma Market: Region Footprint
3.4.2 Immunotherapy for Neuroblastoma Market: Company Product Type Footprint
3.4.3 Immunotherapy for Neuroblastoma Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Immunotherapy for Neuroblastoma Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Immunotherapy for Neuroblastoma Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Immunotherapy for Neuroblastoma Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Immunotherapy for Neuroblastoma Consumption Value Comparison
4.2.1 United States VS China: Immunotherapy for Neuroblastoma Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Immunotherapy for Neuroblastoma Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Immunotherapy for Neuroblastoma Companies and Market Share, 2018-2023
4.3.1 United States Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
4.4 China Based Companies Immunotherapy for Neuroblastoma Revenue and Market Share, 2018-2023
4.4.1 China Based Immunotherapy for Neuroblastoma Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
4.5 Rest of World Based Immunotherapy for Neuroblastoma Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Immunotherapy for Neuroblastoma Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Dinutuximab
5.2.2 Naxitamab
5.2.3 Other
5.3 Market Segment by Type
5.3.1 World Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
5.3.2 World Immunotherapy for Neuroblastoma Market Size by Type (2024-2029)
5.3.3 World Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Immunotherapy for Neuroblastoma Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
6.3.2 World Immunotherapy for Neuroblastoma Market Size by Application (2024-2029)
6.3.3 World Immunotherapy for Neuroblastoma Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 United Therapeutics
7.1.1 United Therapeutics Details
7.1.2 United Therapeutics Major Business
7.1.3 United Therapeutics Immunotherapy for Neuroblastoma Product and Services
7.1.4 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 United Therapeutics Recent Developments/Updates
7.1.6 United Therapeutics Competitive Strengths & Weaknesses
7.2 Y-mAbs Therapeutics
7.2.1 Y-mAbs Therapeutics Details
7.2.2 Y-mAbs Therapeutics Major Business
7.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product and Services
7.2.4 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Y-mAbs Therapeutics Recent Developments/Updates
7.2.6 Y-mAbs Therapeutics Competitive Strengths & Weaknesses
7.3 EUSA Pharma
7.3.1 EUSA Pharma Details
7.3.2 EUSA Pharma Major Business
7.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Product and Services
7.3.4 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 EUSA Pharma Recent Developments/Updates
7.3.6 EUSA Pharma Competitive Strengths & Weaknesses
7.4 ANI Pharmaceuticals
7.4.1 ANI Pharmaceuticals Details
7.4.2 ANI Pharmaceuticals Major Business
7.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.4.4 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 ANI Pharmaceuticals Recent Developments/Updates
7.4.6 ANI Pharmaceuticals Competitive Strengths & Weaknesses
7.5 Baxter Healthcare
7.5.1 Baxter Healthcare Details
7.5.2 Baxter Healthcare Major Business
7.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Product and Services
7.5.4 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Baxter Healthcare Recent Developments/Updates
7.5.6 Baxter Healthcare Competitive Strengths & Weaknesses
7.6 Ingenus Pharmaceuticals
7.6.1 Ingenus Pharmaceuticals Details
7.6.2 Ingenus Pharmaceuticals Major Business
7.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.6.4 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
7.6.6 Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
7.7 Pfizer
7.7.1 Pfizer Details
7.7.2 Pfizer Major Business
7.7.3 Pfizer Immunotherapy for Neuroblastoma Product and Services
7.7.4 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Pfizer Recent Developments/Updates
7.7.6 Pfizer Competitive Strengths & Weaknesses
7.8 Hikma Pharmaceuticals
7.8.1 Hikma Pharmaceuticals Details
7.8.2 Hikma Pharmaceuticals Major Business
7.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.8.4 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 Hikma Pharmaceuticals Recent Developments/Updates
7.8.6 Hikma Pharmaceuticals Competitive Strengths & Weaknesses
7.9 Teva Pharmaceuticals
7.9.1 Teva Pharmaceuticals Details
7.9.2 Teva Pharmaceuticals Major Business
7.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
7.9.4 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Teva Pharmaceuticals Recent Developments/Updates
7.9.6 Teva Pharmaceuticals Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Immunotherapy for Neuroblastoma Industry Chain
8.2 Immunotherapy for Neuroblastoma Upstream Analysis
8.3 Immunotherapy for Neuroblastoma Midstream Analysis
8.4 Immunotherapy for Neuroblastoma Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Immunotherapy for Neuroblastoma Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Immunotherapy for Neuroblastoma Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Immunotherapy for Neuroblastoma Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Immunotherapy for Neuroblastoma Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Immunotherapy for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Immunotherapy for Neuroblastoma Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Immunotherapy for Neuroblastoma Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Immunotherapy for Neuroblastoma Players in 2022
Table 12. World Immunotherapy for Neuroblastoma Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Immunotherapy for Neuroblastoma Company Evaluation Quadrant
Table 14. Head Office of Key Immunotherapy for Neuroblastoma Player
Table 15. Immunotherapy for Neuroblastoma Market: Company Product Type Footprint
Table 16. Immunotherapy for Neuroblastoma Market: Company Product Application Footprint
Table 17. Immunotherapy for Neuroblastoma Mergers & Acquisitions Activity
Table 18. United States VS China Immunotherapy for Neuroblastoma Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Immunotherapy for Neuroblastoma Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
Table 21. United States Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 23. China Based Immunotherapy for Neuroblastoma Companies, Headquarters (Province, Country)
Table 24. China Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 26. Rest of World Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 29. World Immunotherapy for Neuroblastoma Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (USD Million)
Table 31. World Immunotherapy for Neuroblastoma Market Size by Type (2024-2029) & (USD Million)
Table 32. World Immunotherapy for Neuroblastoma Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (USD Million)
Table 34. World Immunotherapy for Neuroblastoma Market Size by Application (2024-2029) & (USD Million)
Table 35. United Therapeutics Basic Information, Area Served and Competitors
Table 36. United Therapeutics Major Business
Table 37. United Therapeutics Immunotherapy for Neuroblastoma Product and Services
Table 38. United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. United Therapeutics Recent Developments/Updates
Table 40. United Therapeutics Competitive Strengths & Weaknesses
Table 41. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 42. Y-mAbs Therapeutics Major Business
Table 43. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product and Services
Table 44. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Y-mAbs Therapeutics Recent Developments/Updates
Table 46. Y-mAbs Therapeutics Competitive Strengths & Weaknesses
Table 47. EUSA Pharma Basic Information, Area Served and Competitors
Table 48. EUSA Pharma Major Business
Table 49. EUSA Pharma Immunotherapy for Neuroblastoma Product and Services
Table 50. EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. EUSA Pharma Recent Developments/Updates
Table 52. EUSA Pharma Competitive Strengths & Weaknesses
Table 53. ANI Pharmaceuticals Basic Information, Area Served and Competitors
Table 54. ANI Pharmaceuticals Major Business
Table 55. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 56. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. ANI Pharmaceuticals Recent Developments/Updates
Table 58. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 59. Baxter Healthcare Basic Information, Area Served and Competitors
Table 60. Baxter Healthcare Major Business
Table 61. Baxter Healthcare Immunotherapy for Neuroblastoma Product and Services
Table 62. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Baxter Healthcare Recent Developments/Updates
Table 64. Baxter Healthcare Competitive Strengths & Weaknesses
Table 65. Ingenus Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Ingenus Pharmaceuticals Major Business
Table 67. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 68. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Ingenus Pharmaceuticals Recent Developments/Updates
Table 70. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Pfizer Basic Information, Area Served and Competitors
Table 72. Pfizer Major Business
Table 73. Pfizer Immunotherapy for Neuroblastoma Product and Services
Table 74. Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Pfizer Recent Developments/Updates
Table 76. Pfizer Competitive Strengths & Weaknesses
Table 77. Hikma Pharmaceuticals Basic Information, Area Served and Competitors
Table 78. Hikma Pharmaceuticals Major Business
Table 79. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 80. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Hikma Pharmaceuticals Recent Developments/Updates
Table 82. Teva Pharmaceuticals Basic Information, Area Served and Competitors
Table 83. Teva Pharmaceuticals Major Business
Table 84. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 85. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 86. Global Key Players of Immunotherapy for Neuroblastoma Upstream (Raw Materials)
Table 87. Immunotherapy for Neuroblastoma Typical Customers
Table 1. World Immunotherapy for Neuroblastoma Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Immunotherapy for Neuroblastoma Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Immunotherapy for Neuroblastoma Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Immunotherapy for Neuroblastoma Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Immunotherapy for Neuroblastoma Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Immunotherapy for Neuroblastoma Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Immunotherapy for Neuroblastoma Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Immunotherapy for Neuroblastoma Players in 2022
Table 12. World Immunotherapy for Neuroblastoma Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Immunotherapy for Neuroblastoma Company Evaluation Quadrant
Table 14. Head Office of Key Immunotherapy for Neuroblastoma Player
Table 15. Immunotherapy for Neuroblastoma Market: Company Product Type Footprint
Table 16. Immunotherapy for Neuroblastoma Market: Company Product Application Footprint
Table 17. Immunotherapy for Neuroblastoma Mergers & Acquisitions Activity
Table 18. United States VS China Immunotherapy for Neuroblastoma Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Immunotherapy for Neuroblastoma Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
Table 21. United States Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 23. China Based Immunotherapy for Neuroblastoma Companies, Headquarters (Province, Country)
Table 24. China Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 26. Rest of World Based Immunotherapy for Neuroblastoma Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Immunotherapy for Neuroblastoma Revenue Market Share (2018-2023)
Table 29. World Immunotherapy for Neuroblastoma Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (USD Million)
Table 31. World Immunotherapy for Neuroblastoma Market Size by Type (2024-2029) & (USD Million)
Table 32. World Immunotherapy for Neuroblastoma Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (USD Million)
Table 34. World Immunotherapy for Neuroblastoma Market Size by Application (2024-2029) & (USD Million)
Table 35. United Therapeutics Basic Information, Area Served and Competitors
Table 36. United Therapeutics Major Business
Table 37. United Therapeutics Immunotherapy for Neuroblastoma Product and Services
Table 38. United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. United Therapeutics Recent Developments/Updates
Table 40. United Therapeutics Competitive Strengths & Weaknesses
Table 41. Y-mAbs Therapeutics Basic Information, Area Served and Competitors
Table 42. Y-mAbs Therapeutics Major Business
Table 43. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product and Services
Table 44. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Y-mAbs Therapeutics Recent Developments/Updates
Table 46. Y-mAbs Therapeutics Competitive Strengths & Weaknesses
Table 47. EUSA Pharma Basic Information, Area Served and Competitors
Table 48. EUSA Pharma Major Business
Table 49. EUSA Pharma Immunotherapy for Neuroblastoma Product and Services
Table 50. EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. EUSA Pharma Recent Developments/Updates
Table 52. EUSA Pharma Competitive Strengths & Weaknesses
Table 53. ANI Pharmaceuticals Basic Information, Area Served and Competitors
Table 54. ANI Pharmaceuticals Major Business
Table 55. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 56. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. ANI Pharmaceuticals Recent Developments/Updates
Table 58. ANI Pharmaceuticals Competitive Strengths & Weaknesses
Table 59. Baxter Healthcare Basic Information, Area Served and Competitors
Table 60. Baxter Healthcare Major Business
Table 61. Baxter Healthcare Immunotherapy for Neuroblastoma Product and Services
Table 62. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Baxter Healthcare Recent Developments/Updates
Table 64. Baxter Healthcare Competitive Strengths & Weaknesses
Table 65. Ingenus Pharmaceuticals Basic Information, Area Served and Competitors
Table 66. Ingenus Pharmaceuticals Major Business
Table 67. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 68. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Ingenus Pharmaceuticals Recent Developments/Updates
Table 70. Ingenus Pharmaceuticals Competitive Strengths & Weaknesses
Table 71. Pfizer Basic Information, Area Served and Competitors
Table 72. Pfizer Major Business
Table 73. Pfizer Immunotherapy for Neuroblastoma Product and Services
Table 74. Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Pfizer Recent Developments/Updates
Table 76. Pfizer Competitive Strengths & Weaknesses
Table 77. Hikma Pharmaceuticals Basic Information, Area Served and Competitors
Table 78. Hikma Pharmaceuticals Major Business
Table 79. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 80. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. Hikma Pharmaceuticals Recent Developments/Updates
Table 82. Teva Pharmaceuticals Basic Information, Area Served and Competitors
Table 83. Teva Pharmaceuticals Major Business
Table 84. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product and Services
Table 85. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 86. Global Key Players of Immunotherapy for Neuroblastoma Upstream (Raw Materials)
Table 87. Immunotherapy for Neuroblastoma Typical Customers
LIST OF FIGURES
Figure 1. Immunotherapy for Neuroblastoma Picture
Figure 2. World Immunotherapy for Neuroblastoma Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Immunotherapy for Neuroblastoma Total Market Size (2018-2029) & (USD Million)
Figure 4. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 13. Immunotherapy for Neuroblastoma Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 16. World Immunotherapy for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 18. China Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 23. India Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Immunotherapy for Neuroblastoma by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Immunotherapy for Neuroblastoma Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Immunotherapy for Neuroblastoma Markets in 2022
Figure 27. United States VS China: Immunotherapy for Neuroblastoma Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Immunotherapy for Neuroblastoma Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Immunotherapy for Neuroblastoma Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 31. Dinutuximab
Figure 32. Naxitamab
Figure 33. Other
Figure 34. World Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2029)
Figure 35. World Immunotherapy for Neuroblastoma Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 37. Hospital
Figure 38. Clinic
Figure 39. Other
Figure 40. Immunotherapy for Neuroblastoma Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Figure 1. Immunotherapy for Neuroblastoma Picture
Figure 2. World Immunotherapy for Neuroblastoma Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Immunotherapy for Neuroblastoma Total Market Size (2018-2029) & (USD Million)
Figure 4. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Immunotherapy for Neuroblastoma Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Immunotherapy for Neuroblastoma Revenue (2018-2029) & (USD Million)
Figure 13. Immunotherapy for Neuroblastoma Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 16. World Immunotherapy for Neuroblastoma Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 18. China Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 23. India Immunotherapy for Neuroblastoma Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Immunotherapy for Neuroblastoma by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Immunotherapy for Neuroblastoma Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Immunotherapy for Neuroblastoma Markets in 2022
Figure 27. United States VS China: Immunotherapy for Neuroblastoma Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Immunotherapy for Neuroblastoma Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Immunotherapy for Neuroblastoma Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 31. Dinutuximab
Figure 32. Naxitamab
Figure 33. Other
Figure 34. World Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2029)
Figure 35. World Immunotherapy for Neuroblastoma Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 37. Hospital
Figure 38. Clinic
Figure 39. Other
Figure 40. Immunotherapy for Neuroblastoma Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
